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Abstract
A simple biochemical method to isolate mRNAs pulled down with a transfected, biotinylated microRNA was used to identify
direct target genes of miR-34a, a tumor suppressor gene. The method reidentified most of the known miR-34a regulated
genes expressed in K562 and HCT116 cancer cell lines. Transcripts for 982 genes were enriched in the pull-down with miR-
34a in both cell lines. Despite this large number, validation experiments suggested that ,90% of the genes identified in
both cell lines can be directly regulated by miR-34a. Thus miR-34a is capable of regulating hundreds of genes. The
transcripts pulled down with miR-34a were highly enriched for their roles in growth factor signaling and cell cycle
progression. These genes form a dense network of interacting gene products that regulate multiple signal transduction
pathways that orchestrate the proliferative response to external growth stimuli. Multiple candidate miR-34a–regulated
genes participate in RAS-RAF-MAPK signaling. Ectopic miR-34a expression reduced basal ERK and AKT phosphorylation and
enhanced sensitivity to serum growth factor withdrawal, while cells genetically deficient in miR-34a were less sensitive.
Fourteen new direct targets of miR-34a were experimentally validated, including genes that participate in growth factor
signaling (ARAF and PIK3R2) as well as genes that regulate cell cycle progression at various phases of the cell cycle (cyclins
D3 and G2, MCM2 and MCM5, PLK1 and SMAD4). Thus miR-34a tempers the proliferative and pro-survival effect of growth
factor stimulation by interfering with growth factor signal transduction and downstream pathways required for cell division.
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Introduction
microRNAs (miRNAs) that promote cell differentiation, inhibit
cell proliferation, or enhance DNA damage or stress-induced cell
cycle arrest or death, and whose expression is reduced in some
cancers, are candidate tumor suppressor genes [1]. One of the most
well studied tumor suppressor miRNAs is miR-34a. Depending on
cellular context [2], ectopic over-expression of miR-34a induces cell
cycle arrest [3], senescence [4] or apoptosis [5]. miR-34a is up-
regulated by p53in responseto DNA damage [6–8], but canalsobe
transcriptionally activated independently of p53 [9,10]. miR-34a is
located on chromosome 1p36, a locus deleted in neuroblastoma,
breast, thyroid, and cervical cancer [11,12]. In other cancers, miR-
34a expression is epigenetically reduced by hypermethylation [13].
miR-34a administration can inhibit tumor outgrowth in mice [4].
Thus miR-34a satisfies the criteria for a tumor suppressor gene.
The best way to understand the function of a miRNA is to
identify the genes it regulates. In this study we sought to
understand how miR-34a acts as a tumor suppressor by identifying
its direct target genes. However, target gene identification is not
straightforward because of the partial complementarity of the
short ,22 nt miRNA sequence with the miRNA recognition
element (MRE) of the target gene [14]. MRE pairing to the
miRNA seed region (nt 2–7) contributes significantly to target gene
recognition and is the basis for the most successful target gene
prediction algorithms [15,16]. However, a perfect seed match is
not necessary [17,18] and does not guarantee targeting [19].
miRNA target prediction algorithms typically predict hundreds to
thousands of putative miRNA target genes, but most predicted
target genes are not bona fide targets and the best algorithms
sometimes miss key targets [17,19–21]. It is unclear how many
target genes are in fact regulated by a given miRNA in any
physiological context. Analysis of genes whose mRNA or protein
expression decreases when a miRNA is overexpressed or increases
when it is antagonized identifies genes that may be either direct
targets or indirectly regulated [22]. Biochemical methods to
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potentially provide a more direct way to identify miRNA-
regulated target genes [23–25]. However, immunoprecipitation
has mostly been used to define the general features of miRNA-
regulated mRNAs and their MREs, rather than to identify the
targets of a particular miRNA.
Already 36 putative miR-34a targets have been validated by
luciferase reporter assays. These targets strongly support miR-
34a’s role as a tumor suppressor. They include genes that promote
cell cycle progression through the G1/S transition (CCND1,
CCNE2, CDK4, CDK6, MYC, MYCN and E2F3) [3,8,10,12,26],
enhance transcription (MYB, HNF4A and FOXP1) [9,27,28] or
growth factor signaling (MET, MEK1, AXL and RRAS) [8,29–32],
inhibit apoptosis (BCL2) [33] or p53 activity (YY1, MTA2, SIRT1
and MAGE-A) [5,32,34,35], and promote stem cell survival
(NOTCH1, NOTCH2, LEF1 WNT1, DLL1, JAG1 and CD44)
[32,36–40]. The diversity of direct miR-34a targets suggests that
miR-34a acts pleiotropically by regulating many genes.
To identify additional direct target genes of miR-34a without
bias and understand better how miR-34a functions, we optimized
a simple biochemical method to isolate mRNAs that bind to
transfected biotinylated (Bi-)miR-34a [41,42]. mRNAs significant-
ly enriched in the Bi-miRNA pull-down with streptavidin relative
to their cellular expression were candidate targets. The pull-down
was performed in two unrelated cancer cell lines, K562
erythroleukemia cells and HCT116 colon carcinoma cells. p53
activates transcription of miR-34a [8]. Under basal conditions,
p53-sufficient HCT116 cells highly express miR-34a, while p53-
null K562 cells do not express it above background (data not
shown). We selected disparate cell lines to identify genes that may
be regulated in multiple cell types or more specifically in a
particular context. Several thousand genes were significantly
enriched in the miR-34a pull-down in each cell line and 982
were significantly enriched in both cell lines. Most known miR-34a
target mRNAs expressed in these cells were pulled down with
miR-34a. Despite the large number of genes significantly enriched
in the miR-34a pull-down, 91% of a random list of 11 genes
enriched in both cell lines contained miR-34a-regulated 39UTR
sequences. These results suggest that the pull-down is quite specific
and that miR-34a potentially directly regulates hundreds of
genes. Bioinformatic analysis of the pulled down genes or of
genes down-regulated after miR-34a transfection suggested that
miR-34a regulates a dense network of genes that transduce
proliferative signals arising from growth factor stimulation.
Multiple candidate target genes participate in RAS-RAF-MAPK
signaling. In fact miR-34a knockout reduced sensitivity to growth
factor withdrawal by serum starvation, while miR-34a transfection
led to increased vulnerability. Fourteen novel miR-34a targets
identified by the pull-down in both cell lines were experimentally
verified, including ARAF and PIK3R2 in the RAS-RAF-MAPK
pathway, and additional target genes required for cell cycle
progression, including cyclins D3 and G2, MAD2L2, MCM2,
MCM5 and PLK1.
Results
Isolation of mRNAs bound to a transfected
biotinylated–miRNA
We modified a method [5] for capturing miRNA-mRNA
complexes using streptavidin-coated beads from cells transfected
with miR-34a biotinylated at the 39-end of the mature strand.
Control samples were transfected with a biotinylated C. elegans
miRNA (Bi-cel-miR-67) (Figure 1A). Biotinylation did not
interfere with miRNA-mediated gene suppression as measured
by luciferase reporter assay (Figure 1B). Over-expressing Bi-miR-
34a or miR-34a in K562 cells also similarly suppressed expression
of known miR-34a target genes (Figure 1C). Moreover, immuno-
precipitation of HA-tagged Ago1 or Ago2 in K562 cells
cotransfected with Bi-miR-34a specifically enriched for miR-34a
by ,4-fold and ,6-fold, respectively (Figure 1D). Thus the Bi-
miRNA is incorporated into the RISC and functions like the
unbiotinylated miRNA.
We next optimized conditions to capture known target gene
mRNAs. In the Bi-miR-34a pull-down of K562 cells, known miR-
34a target transcripts CDK4 and CDK6, but not UBC (a
housekeeping gene), were enriched 12 hr after transfection, and
their capture plateaued at 24–48 hr (Figure 1E). Therefore, 24 hr
was chosen for subsequent experiments. The specificity of the pull-
down and applicability to other cell types was verified since CDK4,
CDK6 and MYB mRNAs were consistently enriched by transfec-
tion of Bi-miR-34a, but not Bi-cel-miR-67, in K562 (Figure 1F)
and HCT116 (Figure S1A) cells. Streptavidin beads did not enrich
for non-target SDHA and UBC mRNAs, and the specific target
mRNAs were not pulled down in cells transfected with
unbiotinylated miR-34a (data not shown). miR-34a was specifi-
cally enriched .40-fold in the Bi-miR-34a pull-down compared to
the input lysate (Figure S1B). Modifications of the pull-down to
include formaldehyde cross-linking and/or pre-isolation of RNAs
in high molecular weight cellular fractions reduced the amount of
captured RNA, but did not improve the relative enrichment for
known target gene mRNAs (data not shown). To confirm that
association of Bi-miRNAs with target mRNAs was not a post-lysis
artifact, we performed streptavidin pull-downs after adding Bi-
miR-34a or Bi-cel-miR-67 to cytoplasmic extracts of untransfected
K562 cells. CDK4, CDK6 and MYB mRNAs were not enriched
when Bi-miR-34a was added post-lysis (Figure S1C). The general
applicability of the pull-downs to enrich for miRNA target genes
was also verified for another miRNA, miR-24 in HepG2 cells. Bi-
miR-24 capture enriched for 3 known miR-24 targets (H2AFX,
E2F2 and MYC [43]) by 2–5-fold (Figure 1G).
Sensitivity of the Bi-miR-34a pull-down
We next used gene expression microarrays to identify putative
miR-34a targets captured by Bi-miR-34a in duplicate experiments
from K562 (p53 deficient) and HCT116 cells (p53 proficient)
Author Summary
microRNAs (miRNAs) are small RNAs that regulate gene
expression by binding to mRNAs bearing a partially
complementary sequence. miRNAs decrease the stability
or translation of mRNA targets, leading to reduced protein
expression. Understanding the biological function of a
miRNA requires identifying its targets. Here we developed
a sensitive and specific biochemical method to identify
candidate microRNA targets that are enriched by pull-
down with a tagged, transfected microRNA mimic. The
method was applied to miR-34a, a miRNA that inhibits cell
proliferation. We found that miR-34a can potentially
regulate hundreds of genes. Computational analysis of
these genes suggested a novel function for miR-34a—
suppression of the pro-proliferative response to diverse
growth factors. This function complements the previously
known role of miR-34a in blocking cell cycle progression.
Thus, by reducing the expression of an extensive network
of genes, miR-34a dampens growth factor signaling as well
as its downstream consequences, promotion of cell
survival and proliferation.
miR-34a Inhibits Growth Factor Signaling
PLoS Genetics | www.plosgenetics.org 2 November 2011 | Volume 7 | Issue 11 | e1002363Figure 1. The Biotin-miRNA pulldown method. (A) Schematic of the Bi-miRNA pull-down (PD) assay. (B) Activity of 39-biotinylated miR-34a (Bi-
miR-34a) is similar to unbiotinylated miR-34a mimics by dual luciferase assay performed in HeLa cells cotransfected with psiCHECK-2 vector (black) or
psi-CHECK-2 bearing a perfectly complementary sequence to miR-34a (psiCHECK-2-AS-miR-34a, white). Transfection with cel-miR-67 is the control
(CTL). Luciferase expression was assayed after 24 hr; results are normalized to cells transfected with the luciferase vector and the CTL miRNA. (C) Bi-
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input in Bi-miR-34a-transfected cells were separately normalized
to their levels in Bi-cel-miR-67-transfected cells. For each
biological replicate, the ratio of the abundance of the pull-down
mRNA compared to the input mRNA for cells transfected with Bi-
miR-34a versus Bi-cel-miR-67 was calculated, averaged and used
to define the enrichment ratio {Bi-miR-34a PD/Bi-cel-miR-67
PD}/{Bi-miR-34a input/Bi-cel-miR-67 input}. Normalizing to
the input improved identification of true targets in 2 ways – by
reducing the background caused by highly abundant mRNAs that
associate with streptavidin beads nonspecifically and by incorpo-
rating a measure of mRNA knockdown into the denominator of
the ratio.
The miR-34a pull-downs enriched for 2416 genes in HCT116
cells (by $1 standard deviation (SD), enrichment ratio $2.5) and
for 2816 genes in K562 cells ($1 SD, enrichment ratio $3.3)
(Figure 2A). The overlap of genes enriched $1 SD in both of these
unrelated cell lines was 982 genes. To determine the sensitivity of
the pull-down, we first looked at how many of the 36 published
targets of miR-34a were captured in the K562 or HCT116 pull-
downs (Figure 2B). Of the known expressed targets, 22 of 31
mRNAs (71%) were enriched in HCT116 cells and 14 of 29 (48%)
were enriched in K562 cells. It should be noted that the choice of
cut-off is somewhat arbitrary. Two additional known targets had
enrichment ratios of 2.5–3.2 in K562 cells. The enrichment ratio
ranged from 2.7–85. 12 genes were identified in both pull-downs.
The enrichment ratio for the shared hits was not significantly
different in K562 cells, which do not express miR-34a, compared
to HCT116 cells, which do, suggesting that the pull-downs
efficiently captured miR-34a targets even in cells that express
endogenous miR-34a.
Analysis of genes down-regulated by miR-34a
over-expression
To compare the mRNAs that associate with miR-34a to
mRNAs that decrease with miR-34a over-expression, we mea-
sured mRNA abundance in cells transfected with miR-34a or cel-
miR-67 by gene expression microarrays (Table S1). Genes whose
mean mRNA level ratio decreased by at least 20% after miR-34a
transfection were considered to be down-regulated either directly
or indirectly by miR-34a. With this arbitrary cut-off (,1 SD),
2087 genes were down-regulated in HCT116 cells and 945 genes
were down-regulated in K562 cells (Figure 2C). About a third of
these transcripts in both cell lines were also pulled down with Bi-
miR-34a (30% in HCT116, 36% in K562).
Down-regulated and pulled down mRNAs are enriched
for miR-34a seed sequences
Many miRNA targets contain a perfect match to the miRNA
seed region in their 39UTR. We examined the frequency of
39UTR matches to all hexamer sequences in miR-34a in the pull-
down and down-regulated gene sets relative to all genes probed on
the microarray (Figure S2A). Hexamer matches to nt 2–7 in the
miR-34a seed region were significantly enriched in the pull-down
(HCT116 p=1.8E-95; K562 p=2.4E-11) and down-regulated
(HCT116 p=1.7E-24; K562 p=1.0E-11) datasets. There was also
significant enrichment in the HCT116 pull-down genes for nt 13–
19 exact matches, suggesting that base-pairing there enhances
miRNA binding, as has previously been shown [44]. In both cell
lines, seed enrichment was greater for the overlapping set of genes
that was both pulled down and down-regulated by miR-34a. For
genes in this overlap, exact matches to nt 2–7 were 1.8–2.0-fold
more frequent per kb of 39UTR than for all genes on the
microarray. These data suggest that genes in the overlap may be
more likely to be direct targets than genes identified by only one
method or that a perfect seed match might enhance miRNA-
mediated mRNA decay.
We next examined hexamer enrichment in the 982 genes
enriched $1 SD in pull-downs from both HCT116 and K562 cells
(Figure S2B). Seed matches were most enriched in the 39UTRs of
these genes, with the nt 2–7 match being the most abundant (1.7
fold more abundant than in all genes on the microarray (p=8.4E-
39). The coding region (CDS) of these genes also contained a
highly significant enrichment for hexamer seed matches (p=6.1E-
13). These results are consistent with recent cross-linked RISC
pull-downs that suggest that 25–50% of MREs may be in the CDS
[23,25]. There was also a modest enrichment of hexamers
matching the seed in the 59UTR (p=0.005). Thus the pull-down
and down-regulated mRNAs were enriched for expected miRNA
target sequence features.
We next analyzed whether mRNA expression of the enriched
genes was reduced by miR-34a transfection in HCT116 cells
(Figure 2D). The mRNAs of the 982 genes enriched in the miR-
34a pull-down by $1 SD in both cell lines were significantly
down-regulated after miR-34a transfection compared to the set of
all genes expressed in the cell (p=4.7E-80). The extent of down-
regulation was comparable to the set of 469 TargetScan-predicted,
evolutionarily conserved targets of miR-34a and significantly
greater than in the larger list of 2904 poorly conserved,
TargetScan-predicted genes (p=1.6E-20). Increasing the cutoff
for the enrichment ratio in the pull-down led to a greater
proportion of highly down-regulated genes, indicating that a
higher enrichment ratio correlates with more effective mRNA
degradation and/or that highly enriched mRNAs are more likely
to be miR-34a targets. Thus, the Bi-miR-34a pull-down enriches
for known sequence and gene expression characteristics of bona fide
miRNA targets.
Genes enriched in the miR-34a pull-down of both cell
lines have a high probability of being direct miR-34a
targets
To determine the specificity of the pull-down, we generated a
random list (Table S2) of 11 genes enriched .2.5 fold in both pull-
downs (median enrichment 3.5-fold, range 2.5–17.3). The random
miR-34a efficiently silences known miR-34a targets CDK4, CDK6 and MYB. K562 cells were transfected with CTL miRNA, miR-34a, Bi-CTL or Bi-miR-34a
mimics for 48 hr. Expression was measured by qRT-PCR normalized to GAPDH. The housekeeping genes SDHA and UBC are negative controls. (D)
Cytoplasmic lysates from K562 cells were prepared 48 hr after cotransfection with Bi-CTL (black) miRNA or Bi-miR-34a (white) and a plasmid encoding
HA-Ago1, HA-Ago2, or empty vector. Enrichment of miR-34a by HA immunoprecipitation was measured by qRT-PCR normalized to U6. Enrichment of
Bi-miR-34a in the HA-immunoprecipitates suggests that Bi-miR-34a is incorporated into RISC. (E) Bi-miR-34a pull-downs optimally enrich targets 24o r
48 hr after transfection. K562 cells were transfected in duplicate with Bi-CTL (black) or Bi-miR-34a (white) mimics for the indicated times. Enrichment
of known miR-34a targets (CDK4 and CDK6) or control genes (GAPDH and UBC) was assessed by qRT-PCR relative to GAPDH. (F) The streptavidin pull-
down enriches for miR-34a target genes in K562 cells transfected with Bi-CTL (black) or Bi-miR-34a (white) mimics. (G) Known miR-24 target mRNAs
(H2AX, E2F2 and MYC) are also pulled down with Bi-miR-24 in HepG2 cells reverse transfected 48 hr earlier with Bi-CTL (black) or Bi-miR-24 (white).
Enrichment of target mRNAs in (F) and (G) was analyzed by qRT-PCR relative to SDHA. In all panels, data represent mean 6 SD of 3 independent
experiments. *, p,0.05, #,p ,0.01, **, p,0.005, ##,p ,0.001.
doi:10.1371/journal.pgen.1002363.g001
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and FOXP1 were not known when the list was generated). First,
qRT-PCR analysis verified that the random gene mRNAs are
pulled down by Bi-miR-34a and not Bi-cel-miR-67. All 11
mRNAs were enriched (,4–10 fold) by Bi-miR-34a pull-down in
K562 cells, validating the microarray results (Figure 2E). miR-34a
over-expression significantly down-regulated mRNA levels of 9 of
11 genes by 25–90% (Figure 2F). PCYOX1L expression declined by
20%, but the change was not significant. To test whether the
39UTR of each gene could be regulated by miR-34a, the full 39
UTR of each gene was cloned into a dual luciferase reporter
plasmid. miR-34a repressed the 39UTRs of 10 of 11 genes by
,20–80% (Figure 2G). Thus, miR-34a could regulate the 39UTR
of 91% of a random set of genes enriched in both miR-34a pull-
downs. These results suggest that the Bi-miRNA pull-down is
highly specific for identifying direct miRNA targets. An important
implication of the large number of genes in the overlapping target
list and the low false positive rate is that miR-34a is capable of
regulating hundreds of genes.
miR-34a directly regulates growth factor signaling and
cell cycle progression
To understand miR-34a’s biological functions, we analyzed the
cellular pathways whose genes were most enriched in the Bi-miR-
34a pull-downs (Figure 3A). In both K562 and HCT116 cells, Bi-
miR-34a pull-downs enriched for genes in pathways related to
growth factor signaling and cell cycle control. Bi-miR-34a pull-
downs enriched significantly for genes in the EGFR, TGF-b,
interleukin, estrogen, and androgen receptor signaling pathways
(Figure 3A). Many of these pathways utilize common downstream
signaling molecules and have a well-established link to cancer.
Genes in the MAPK pathway, activated by most growth factors,
were highly enriched in the pull-downs for both cell lines. Growth
factor signaling also activates cell proliferation. Genes involved in
cell cycle regulation, especially the G1/S transition, and the p53
response were enriched in both pull-downs, consistent with
previously described targets and roles of miR-34a [3,4,7,8].
We performed a similar pathway enrichment analysis for genes
down-regulated by miR-34a (Figure 3B), which includes both
direct and indirect miR-34a targets. The downstream effects of
growth factor signaling on cell proliferation and p53 activation
were more prominent in the down-regulated genes than in the
pulled-down gene set, especially in p53-sufficient HCT116 cells.
Cell cycle and DNA repair pathways were enriched in genes
down-regulated by miR-34a in both K562 and HCT116 cells.
These results suggest that miR-34a directly inhibits growth factor
signal transduction and cell cycle progression pathways, culmi-
nating in reduced expression of genes needed for cell proliferation.
A pathway enrichment analysis of the TargetScan-predicted
targets of miR-34a (Figure S3) also highlighted the most
significantly enriched pathways in the experimental pull-down
and down-regulated gene sets, notably TGFb and MAPK
signaling and cell cycle and G1/S transition. However, the
significance of the enrichment was weaker and the strong role of
miR-34a in growth factor signaling was less obvious.
miR-34a regulates a dense network of genes involved in
signal transduction and cell cycle progression
To begin to understand regulation of growth factor signaling
and cell proliferation at the gene level by miR-34a, an interactome
of pulled down or down-regulated genes in HCT116 cells that
participate in the significantly enriched pathways was generated
(Figure 4). miR-34a potentially regulates the expression of critical
genes involved in virtually every step and branch of growth factor
signal transduction from ligand binding to downstream growth-
promoting transcription factors. The putative direct targets
included genes encoding multiple TGFb and FGF isoforms,
receptors for EGF, FGF, and insulin, and several oncogenic
receptor tyrosine kinases, including MET and AXL. Several genes
operating proximally in signal transduction, including SRC, PLCG1
and VAV2, were selectively pulled down. miR-34a targets also
included protein kinase subunits that activate downstream
signaling, including subunits of protein kinase A and C. In the
RAS-RAF-MAPK signal transduction pathway, putative directly
regulated genes included RRAS and RASA2, ARAF and BRAF,
JAK2, and 11 MAPK genes. Although knockdown of most of the
targets would be expected to inhibit cellular activation by diverse
growth factors, the genes also encode for some important
inhibitors, including the ubiquitin ligase CBLC, RASA2, and 5
DUSP genes (MAPK phosphatases). The pull-down also captured
76 transcripts of transcription factors, including some that
orchestrate the transcriptional response to signal transduction
(including STAT3, CREB1 and CREB3, SP1, ELK1 and SMAD4).
A major downstream effect of growth factor signaling and its
activated transcription factors is to stimulate cell proliferation.
miR-34a is already known to suppress E2F3 and some key cyclins
and cyclin-dependent kinases that regulate the G1/S transition.
The miR-34a pull-down enriched for additional cyclins (CCND3,
CCNG2), but also for transcripts of genes that inhibit the kinases
that promote exit from G1 (CDKN1C that encodes p57(KIP2),
CDKN2A (p14(ARF)). Other enriched transcripts include MCM5,
whose product is required to initiate DNA replication, and several
genes required for mitosis (PLK1, MAD2L2 and CDC23). Ectopic
miR-34a expression led to down-regulation of mRNAs for many
genes needed to replicate DNA, including 2 members of the
initiating complex that assembles at origins of DNA replication, 7
Figure 2. miR-34a pulls down transcripts of known and novel direct targets of miR-34a. (A) Overlap of genes enriched $1 SD in gene
expression microarray analysis of Bi-miR-34a pull-downs from HCT116 and K562 cells. (B) Enrichment of previously described miR-34a target gene
mRNAs in Bi-miR-34a pull-downs from HCT116 and K562 cells. Genes enriched $1 SD are indicated in bold. Abs=not expressed. (C) Genes down-
regulated by $20% after miR-34a over-expression. (D) mRNA expression of candidate miR-34a targets identified by Bi-miR-34a pull-down in both
HCT116 and K562 cells decreases after miR-34a over-expression. Cumulative distribution plots compare the extent of mRNA reduction of genes
enriched to varying degrees in the Bi-miR-34a pull-down with conserved (cons) or all TargetScan (TScan)-predicted targets. Genes whose mRNAs are
more highly enriched in the pull-down are progressively more likely to have reduced expression. (E) Pull-down of 11 mRNAs randomly selected from
the set of genes enriched $2.5-fold by microarray in both HCT116 and K562 Bi-miR-34a pull-downs is confirmed by qRT-PCR relative to SDHA in K562
cells transfected for 24 hr with Bi-CTL (black) or Bi-miR-34a (white). UBC is a negative control and E2F3 is a positive control. Three previously validated
miR-34a targets (AXL, CDK4 and FOXP1) in the random list of genes are indicated in bold. (F) miR-34a over-expression significantly decreases the
expression of 9 of 11 of the randomly chosen candidate target genes. K562 cells were transfected with CTL miRNA (black) or miR-34a (white) mimics
for 72 hr. Expression of random targets was measured by qRT-PCR normalized to GAPDH. Expression of 2 randomly selected genes (ACSM3 and
PCYOX1L) and the housekeeping mRNA UBC didn’t change significantly. (G) miR-34a targets the 39UTR of 10 of 11 randomly chosen targets. Luciferase
activity was measured 48 hr after HeLa cells were cotransfected with the luciferase reporter psiCHECK2 bearing the 39UTR of each gene and CTL
miRNA or miR-34a mimics. Results obtained after miR-34a transfection were normalized to CTL miRNA. In (E–G), data represent mean 6 SD of 3
independent experiments. *, p,0.05, #,p ,0.01, **, p,0.005, ##,p ,0.001.
doi:10.1371/journal.pgen.1002363.g002
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components of the RFC complex, a cofactor for DNA polymerase.
These results suggest that miR-34a not only interferes with the
signaling that transduces the growth factor response, but also
directly and indirectly suppresses the expression of numerous
genes needed for cell proliferation.
miR-34a regulates cellular responses to growth factor
signaling
The Ras–extracellular signal-regulated kinase (ERK) and
phosphoinositide 3-kinase (PI3K)–AKT pathways are key trans-
ducers of the cellular response to growth factors. Since many
candidatemiR-34a targetgene productsactinpathwaysconverging
on ERK and AKT activation, we analyzed the effect of miR-34a
over-expression on ERK and AKT phosphorylation. miR-34a
transfection reduced basal phosphorylation of ERK and AKT in
HCT116 and HeLa cells (Figure 5A, 5B), but not in A549 cells
(Figure S4A). miR-34a over-expression both reduced basal
proliferation in the absence of serum and blunted the ability of
HCT116 (Figure 5C), HeLa (Figure 5D) and A549 (Figure S4B)
cells to proliferate in response to serum growth factors. Conversely,
immortalized mouse embryonic fibroblasts (MEFs) genetically
deficient in miR-34a were more resistant to serum starvation than
WT MEFs (Figure 5E). Apoptosis measured by annexin V and
Figure 3. Genes in the Bi-miR-34a pull-down or down-regulated by miR-34a over-expression are enriched in growth factor
signaling, cell cycle progression, and DNA repair pathways. Network of canonical pathways (Wikipathways and KEGG) significantly enriched
for genes identified by Bi-miR-34a pull-down (A) or down-regulated following miR-34a over-expression (B) in HCT116 and K562 cells. Each pathway is
represented by a node in the network. The node size increases with the number of identified genes in the pathway and the node color represents the
p-value based on the hypergeometric distribution (see key). Pathways that are not significantly enriched in an experiment are still shown, but are in
gray. The number of genes shared between two pathways is represented by an edge whose thickness increases with the number of shared genes.
The pull-down enriched pathways (A) suggest that miR-34a extensively targets growth factor, signal transduction and cell cycle control pathways.
The integrated outcome of both direct and indirect effects of miR-34a on gene expression in (B) is suppression of expression of genes participating in
downstream signaling, cell cycle and DNA repair pathways.
doi:10.1371/journal.pgen.1002363.g003
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34a
2/2 MEFs compared to wild-type MEFs after 24 hours of
serum starvation (Figure 5F). Despite the strong difference in cell
survival in cells deficient in miR-34a, expression of several known
miR-34a targets did not differ significantly between wild-type and
miR-34a
2/2 MEFs (data not shown). The lack of a notable
difference may be due in part to compensatory up-regulation of
miR-34b and miR-34c in miR-34a
2/2 MEFs (Figure 5G). These
data suggest that miR-34a dampens the basal state of activation of
proliferative and pro-survival pathways mediated by AKT and
ERK by down-modulating multiple genes whose products contrib-
ute to their phosphorylation.
miR-34a directly targets genes that regulate ERK and AKT
phosphorylation
To determine whether some of the candidate miR-34a target
genes identified in the pull-down that participate in growth factor
signaling are bona fide targets, we next tested miR-34a targeting of
selected receptor-proximal (AXL, MET and PIK3R2) and more
downstream (ARAF and MEK1) components of ERK and AKT
signal transduction pathways. These 5 genes were both pulled
down with Bi-miR-34a and down-regulated by miR-34a in
HCT116 cells. ARAF is a serine/threonine protein kinase that
phosphorylates and activates MEK1, which in turn phosphorylates
ERK [45]. AXL is a receptor tyrosine kinase that stimulates cell
Figure 4. Interactome of genes in the enriched canonical pathways pulled down with Bi-miR-34a and/or down-regulated by miR-
34a over-expression. Interactome of products of genes identified by Bi-miR-34a pull-down (red) or down-regulated by miR-34a over-expression
(blue) in significantly enriched pathways (Figure 3) in HCT116 cells. Edges represent physical interactions. A dense network of genes involved in
growth factor signaling and downstream effects on cell cycle progression and DNA repair is implicated.
doi:10.1371/journal.pgen.1002363.g004
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regulatory subunit of PI3K [48] and MET is a tyrosine kinase
receptor that activates both PI3K and RAS [49]. AXL, MET and
MEK1 are described miR-34a targets [8,29,31], although AXL and
MEK1 were not known when these studies were performed.
The transcripts of all 5 genes were enriched 3–15-fold in the Bi-
miR-34a pull-down by qRT-PCR, validating the microarray
results (Figure 6A). Furthermore, over-expression of miR-34a
down-regulated both the mRNA and protein levels of all 5 genes
(Figure 6B, 6C). All but ARAF are also predicted miR-34a targets
by TargetScan. To determine whether these genes are direct miR-
34a targets, we tested the 39UTRs for 4 of the genes (ARAF, AXL,
MEK1 and MET) by luciferase assay. miR-34a reduced reporter
activity of these 39UTRs by ,40–75% (Figure 6D). Using the
PITA algorithm [50] to identify potential MREs in their 39UTRs,
we found 1 potential MRE in AXL, 2 in ARAF, 3 in MEK1,4i n
PIK3R2 and 5 in MET (Figure S4). We tested repression of these
MREs by miR-34a using luciferase assays. All 5 genes contained at
least one miR-34a-responsive MRE (Figure 6E). Point mutations
that disrupt the MRE-miR-34a interaction restored luciferase
Figure 5. miR-34a expression suppresses cellular activation in response to serum growth factors. (A,B) miR-34a over-expression reduces
basal phosphorylation of AKT and ERK as measured by immunoblot 48 hr after transfection of HCT116 (A) and HeLa (B) cells with control (CTL) miRNA
or miR-34a mimics. Abundance of total ERK and AKT doesn’t change. (C,D) miR-34a over-expression reduces cell proliferation in the absence of serum
and suppresses the proliferative response of HCT116 (C) and HeLa (D) cells 24 hr after adding serum. (E) Total numbers of miR-34a
+/+ or miR-34a
2/2
MEFs after 24 hr of culture in 10% serum (10%) or 24 hr in 10% serum followed by 24 hr in 0.1% serum (0.1%). MEFs sufficient for miR-34a were more
sensitive to serum starvation. (F) miR-34a
+/+ MEFs were more prone to apoptosis than miR-34a
2/2 MEFs after 24 hr of culture in reduced serum. (G)
Expression of miR-34 family members in miR-34
+/+ (WT) and miR-34
2/2 MEFs assessed by qRT-PCR. miR-34a
2/2 MEFs expressed higher levels of miR-
34b and miR-34c. In C,D,F, and G, data represent mean 6 SD of 3 independent experiments. *, p,0.05, #,p ,0.01, **, p,0.005, ##,p ,0.001.
doi:10.1371/journal.pgen.1002363.g005
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important genes in PI3K and MAPK signaling are all directly
regulated by miR-34a.
miR-34a pull-downs identify new miR-34a targets that
regulate cell cycle progression
Ectopic expression of miR-34a reduces expression of multiple
direct target genes whose products facilitate the G1/S transition
(CDK4, CDK6, CCND1, CCNE2 and E2F3). The pull-down
identified novel genes acting at the G1/S transition and genes
involved in DNA replication and mitosis. Two cell cycle-regulating
genes enriched in the miR-34a pull-down are in the random gene
list and were already shown (Figure 2C–2E) to be miR-34a-
regulated - CCNG2, which is most highly expressed in late S phase,
and MAD2L2, a component of the mitotic spindle assembly
checkpoint complex. To examine whether some of the other
putative targets that participate in cell cycle progression are direct
miR-34a targets, we focused on genes that were both pulled down
and down-regulated by miR-34a in HCT116 cells (Table S2).
Fourteen cell cycle-regulating genes (CDK4, CDK6, CCNE2, E2F2,
E2F3, E2F5, HDAC1, CDKN2A, MCM5, PKMYT1, PLK1, SMAD4,
MAD2L2 and CCND3) met these criteria. Four of these (CDK4,
CDK6, CCNE2 and E2F3) are known miR-34a targets. We
experimentally tested 5 of the 9 putative novel targets. These
genes were CCND3, a cyclin that binds to CDK4 or CDK6 and
regulates Rb phosphorylation; MCM5, a mini-chromosome
maintenance (MCM) protein involved in initiating DNA replica-
tion, MYT1, a serine/threonine protein kinase that phosphorylates
and inactivates CDC2, thereby negatively regulating cell cycle
progression at the G2/M transition; PLK1, a serine/threonine
protein kinase required for mitotic spindle maturation; and
SMAD4, a TGFb-activated transcription factor that induces G1
arrest and apoptosis. To determine whether these miR-34a pull-
down genes are bona fide miR-34a target genes, we first verified that
their transcripts associate with Bi-miR-34a (Figure 7A). After miR-
34a over-expression, 3 of the 5 genes (MCM5, PLK1 and MYT1)
had reduced mRNA by at least 2-fold (Figure 7B) and all 5 had
significantly reduced protein (Figure 7C). Two other MCM genes,
MCM2 and MCM4, also demonstrated a significant miR-34a-
dependent reduction in mRNA, and their protein levels became
undetectable in miR-34a-transfected cells.
To investigate whether these 5 genes are directly regulated, we
measured changes in luciferase activity in HeLa cells after miR-
34a co-transfection with reporters containing their 39UTRs. The
39UTRs of 4 of 5 of these genes (CCND3, MCM5, PLK1 and
SMAD4) were significantly repressed 30–60% by miR-34a
(Figure 7D). The 39UTR of MYT1, which bound to Bi-miR-34a
and was down-regulated by miR-34a over-expression (Figure 7A,
7B), was not regulated by miR-34a. MYT1 expression could be
regulated by MREs outside the 39UTR or indirectly. PITA and
TargetScan were used to identify miR-34a MREs in the 39UTRs
of CCND3, SMAD4, MCM5, and PLK1 (Figure 7E, Figure S5).
CCND3 MRE1, SMAD4 MRE1 and MCM5 MRE5 were
significantly suppressed by miR-34a (Figure 7E, Figure S5). The
CCND3 and SMAD4 MREs were predicted by TargetScan, while
MCM5 MRE5 contains a miR-34a hexamer seed match.
Mutations that disrupt base pairing with miR-34a rescued
luciferase expression, further confirming that these genes are
direct miR-34a targets. Because the enrichment ratios for MCM2
and MCM4 in the pull-down (,2.3) were close to our cut-off, we
also evaluated whether MCM2 and MCM4 might be direct targets.
MCM2 is a direct target as verified by mRNA enrichment in the
pull-down, decrease in mRNA and protein following miR-34 over-
expression, miR-34a regulation of its 39UTR by luciferase activity
and MRE identification (Figure 7A–7E). However, the MCM4
39UTR was not active in luciferase assays. Collectively, these
findings suggest that miR-34a acts as a master regulator of cell
proliferation, directly suppressing many key genes that control cell
cycle progression.
Discussion
Despite improvements in bioinformatic and experimental tools,
distinguishing the direct targets of a miRNA from indirectly
regulated genes remains challenging [14]. Here we describe a
simple biochemical method to isolate candidate miRNA targets by
streptavidin pull-down of mRNAs that associate with a transfected
Bi-miRNA, and apply it to study miR-34a. Comparison of the set
of mRNAs that directly associate with the Bi-miRNA with
mRNAs down-regulated by miRNA over-expression makes it
possible to distinguish the direct and indirect effects of a miRNA.
Candidates identified by Bi-miR-34a pull-down have properties of
validated miRNA targets: they are enriched for sequences
complementary to the miR-34a seed and tend to decrease in
expression with miR-34a over-expression. Genes that both
decrease in mRNA abundance after over-expression and are
isolated by Bi-miR-34a pull-down are further enriched for seed
matches, indicating that either they are more likely true miR-34a
targets or that a perfect seed match might enhance target mRNA
degradation.
In our analysis we defined candidate direct targets using an
arbitrary enrichment ratio cut-off of 1 SD, which corresponded to
an enrichment of $2.5-fold for HCT116 cells and $3.3-fold for
K562 cells. As the enrichment ratio cut-off was increased, mRNA
suppression after ectopic miR-34a expression increased in tandem
(Figure 2D). A more stringent cut-off would reduce the already low
false positive rate, but also reduce the sensitivity to detect direct
targets (Figure 2B). With this cut-off, we identify 71% of the known
miR-34a targets expressed in HCT116 cells as ‘‘hits’’, but only
48% of the known expressed targets in K562 cells. If we had also
chosen a 2.5-fold cut-off for K562 cells, our sensitivity for picking
targets would have increased to 55%, while a 2-fold cut-off would
have increased it to 69%. Since 10 of 11 genes in the random list
of genes enriched by $2.5 fold by Bi-miR-34a pull-downs in both
cells have 39UTRs regulated directly by miR-34a by luciferase
assay, a lower cut-off for the enrichment ratio might have
increased sensitivity without an unacceptable false discovery rate.
Some bona fide target genes are only enriched in the pull-down by
,2-fold; one of the novel genes we validated by identifying its
MRE (MCM2) was only enriched by 2.3-fold in the pull-down of
both cell lines. The low false positive rate of target identification
demonstrated with the random gene list was also supported by the
high degree of experimental validation of the growth factor
signaling and cell cycle regulatory genes we chose to examine
experimentally (Table S2). In all, we provided experimental
evidence for 14 novel direct targets of miR-34a and identified 14
miR-34a MREs, of which 11 had a perfect hexamer seed match
and the 3 others had perfect matches if G:U wobbles were allowed.
Thus, the majority of genes we identified as regulated by miR-34a
contain canonical 39UTR MREs with good seed pairing. In the
setting of over-expression by transfection, protein levels of all 11
genes we analyzed by immunoblot declined substantially. The few
target genes that we tested for which we did not find miR-34a
regulation of the 39UTR might be false positives or might be direct
targets, regulated by sequences in the 59UTR or CDS. In fact we
found enrichment for hexamer seed matches in these regions in
the mRNAs pulled down with miR-34a, consistent with MRE
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PLoS Genetics | www.plosgenetics.org 10 November 2011 | Volume 7 | Issue 11 | e1002363Figure 6. miR-34a directly inhibits growth factor signaling and signal transduction pathways by regulating novel genes. (A) Five
genes involved in growth factor signaling or signal transduction are pulled down by Bi-miR-34a. HCT116 cells were transfected with Bi-cel-miR67 (CTL
miRNA, black) or Bi-miR-34a (white) mimics for 24 hr and mRNA capture was measured by qRT-PCR normalized to GAPDH. Five of 5 (ARAF, AXL, MEK1,
MET and PIK3R2) genes identified by microarrays, but not housekeeping mRNAs SDHA and UBC, are significantly enriched in the Bi-miR-34a pull-
down. (B) miR-34a decreases ARAF, AXL, MEK1, MET and PIK3R2 mRNAs, measured by qRT-PCR relative to GAPDH, in HCT116 cells transfected with CTL
(black) or miR-34a (white) for 48 hr. UBC is a negative control gene. Relative mRNA levels were normalized to levels in CTL miRNA-transfected cells. (C)
ARAF, AXL, MEK1, MET and PIK3R2 protein levels decline by immunoblot after miR-34a over-expression in HCT116 cells harvested 48 hrs after
transfection with CTL miRNA or miR-34a mimic. Because of the low signal for AXL, an additional experiment probed for AXL with a longer exposure is
shown at right. (D) miR-34a significantly regulates the 39UTR of ARAF, AXL, MEK1 and MET in HeLa cells co-transfected with a dual luciferase reporter
bearing the 39UTR of each gene and CTL miRNA or miR-34a for 48 hr. Insertion of a sequence fully complementary to miR-34a into the Renilla
luciferase 39UTR (AS-34a) is the positive control. Luciferase activity was normalized to results obtained with the empty vector (V). (E) Luciferase
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experiments [23,25].
Known targets may not have been identified by the pull-down
for a variety of reasons. First, not all of the targets in the literature
may be correctly assigned. Second, some known targets, such as
CD44, are only modestly regulated by miR-34a [40]. The ratio
that defines a ‘‘hit’’ is arbitrary. We set a relatively high threshold
for identifying ‘‘hits’’ to maximize the specificity of the method
(especially given the large numbers of enriched mRNAs in the
pull-down), which came at the cost of sensitivity. Some known
targets, which we did not designate hits with our 1 S.D. threshold
of the enrichment ratio (which corresponded to .3.3 in K562
cells) had enrichment ratios of 2.5–3.2 in K562 cells. Other bona
fide targets may have low, but detectable expression levels, and
could have been missed due to the low sensitivity and inter-assay
variability of microarray experiments. In addition to cellular
variation in endogenous miRNA expression and RISC abun-
dance, other context-dependent biological factors, such as target
site accessibility, might vary due to the expression of RNA binding
proteins, which could influence the efficiency of miRNA target site
binding and the mechanism of targeting [51,52]. Cell-type specific
expression of other MRE-containing genes that compete for
miRNA binding could also influence the pull-down enrichment
ratio [53]. Finally, some missed targets are likely to be false
negatives.
Normalizing the pulled down mRNAs to their abundance in the
input cellular mRNA was critical to eliminate from consideration
highly abundant housekeeping mRNAs. Our pull-down method
modified a previously developed protocol [41,42], which did not
normalize the pull-down mRNAs to the input RNA. Many of the
‘‘hits’’ pulled down with Bi-miR-10a included ribosomal mRNAs,
which may represent background binding of very abundant
transcripts. Moreover, the miR-10a ‘‘hits’’ were not enriched for
mRNAs containing miR-10a 39UTR seed matches and were not
down-regulated by miR-10a over-expression. In other work to be
presented elsewhere, the pull-down method was used to identify
genome-wide targets of miR-200c and miR-21. Importantly, the
miR-200c and miR-21 pulled down mRNAs are also enriched for
known targets and for 39UTR seed sequences.
An advantage to the Bi-miRNA pull-down method described
here is its simplicity. In contrast to mRNA expression-based target
identification methods, Bi-miRNA pull-downs should identify only
direct targets, excluding genes whose expression is indirectly
modulated by changes in miRNA expression. Because the degree
of mRNA suppression mediated by miRNAs is often small relative
to changes in protein, methods that rely on changes in mRNA
expression in response to manipulation of miRNA levels will
necessarily miss some direct targets. Although the enrichment ratio
takes into account a reduction in target gene mRNA in its
denominator, the pull-down should not only identify target genes
whose mRNA levels decline, but also those that are regulated
primarily by inhibiting translation. Unlike approaches based on
Ago pull-downs, the Bi-miRNA pull-down identifies the mRNAs
directly associated with a specific miRNA, simplifying analysis of
biological processes regulated by the miRNA.
The method described here without cross-linking does not
directly identify MREs. The streptavidin pull-down method might,
however, readily be modified to include cross-linking, RNase
digestion of unbound mRNA segments and sequencing, similar to
the HITS-CLIP protocol [23,24], to capture not only direct
targets, but also identify MREs of an individual Bi-miRNA.
Isolating RNAs associated with an individual miRNA rather than
all RISC-associated RNAs in cells over-expressing the miRNA of
interest might be a more direct way to define specific target
sequences. Future bioinformatic studies of Bi-miRNA pull-down
datasets could be used to better define in an unbiased manner the
sequence features that dictate miRNA targeting, and could reveal
non-canonical modes of targeting, such as those that contain only
partial seed complementarity [17] or pairing to the central region
of the miRNA [18] or that lie outside the 39UTR. Indeed, in this
work, we enriched for mRNAs with 59UTR and CDS seed
matches, indicating that some direct miR-34a targets may be
regulated outside of their 39UTR.
Only 29% of the 2416 enriched genes in the HCT116 pull-
down had down-regulated mRNA levels by mRNA microarray
analysis after over-expressing miR-34a for one day, while 10 of 11
randomly chosen genes in the pull-down had significantly
decreased mRNA by qRT-PCR analyzed 72 hr after transfection.
Thus although miRNAs may commonly lead to mRNA
degradation, the degree of mRNA down-regulation of most genes
is slight if cells are harvested within a day of transfection. mRNA
microarrays may be too noisy to detect subtle changes in
expression, unless the analysis is performed on many replicates.
Our data also suggest that the kinetics of mRNA degradation may
be slow. The early 24 hr time point used for the assay may have
fortuitously enhanced our ability to capture miRNA-bound
transcripts before too many had been degraded. Indirect effects
of the miRNA are also likely to increase over time. The set of
genes enriched in the miR-34a pull-down of both HCT116 and
K562 cells contains 76 transcription factors or co-factors, whose
suppression would reduce many mRNAs.
One important corollary of our results is that miR-34a likely
directly regulates hundreds of genes. However, further experi-
mental work is needed to assess how many of the hundreds to
thousands of genes whose mRNAs associated with ectopic miR-
34a are actually directly regulated by endogenous miR-34a.
Possibly only a minority of potential targets is indeed directly
regulated in an individual cell at any time. Based on our analysis
(Figure 2D), the genes whose transcripts are most enriched in the
pull-down may be the most significant targets in a given context.
Additional experiments are needed to probe the functional
consequences of miR-34a regulation of the genes we identified
as targets. The directly regulated genes might vary considerably
from cell type to cell type or even in the same cell lineage
depending on differentiation state or environmental conditions.
For this study we focused on the shared targets identified in two
very different types of cells, rather than the ones that were unique
to each cell-type. The pull-down method could be used in the
future to compare miRNA target genes in different cellular
contexts. Notably, the effect of miR-34a on cell signaling differed
in the cancer cells we examined. Basal phosphorylation of AKT
and ERK was reduced by miR-34a over-expression in HCT116
and HeLa cells (Figure 5), but not in A549 cells (Figure S4).
Constitutively active RAS in A549 cells may override the effect of
miR-34a in that context. Our results suggest that a dense network
of genes that participate in common pathways, sometimes with
opposing functions, is capable of being regulated by one miRNA.
Although we observed a clear effect of genetic loss of miR-34a on
the ability to cells to survive growth factor withdrawal, we did not
see reduced expression in miR-34a
2/2 compared to wild-type
reporters bearing PITA-predicted wild-type (WT) MREs from each target gene are significantly repressed in HeLa cells cotransfected with miR-34a.
Point mutations (MT) that disrupt base pairing with miR-34a rescue reporter expression. MRE sequences are provided in Figure S4.
doi:10.1371/journal.pgen.1002363.g006
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PLoS Genetics | www.plosgenetics.org 12 November 2011 | Volume 7 | Issue 11 | e1002363Figure 7. miR-34a pull-downs identify novel miR-34a targets involved in cell cycle progression. (A) Bi-miR-34a pull-down captures
transcripts of cell cycle genes. Enrichment of candidate mRNAs in HCT116 cells transfected with Bi-cel-miR-67 miRNA (CTL, black) or Bi-miR-34a
(white) for 24 hr was assessed by qRT-PCR analysis normalized to GAPDH. SDHA and UBC mRNAs are housekeeping genes not enriched in the pull-
downs. (B) miR-34a over-expression significantly suppresses mRNA levels of 5 of 7 cell cycle genes tested. mRNA expression was analyzed by qRT-PCR
relative to GAPDH performed on total RNA harvested from HCT116 cells transfected with CTL miRNA (black) or miR-34a (white) mimics for 48 hr. Two
candidate target genes (CCND3 and SMAD4) and the housekeeping genes SDHA and UBC are not significantly altered. (C) Protein levels of 6 of 6 cell
cycle genes examined decrease with miR-34a over-expression. HCT116 cells were transfected with CTL miRNA or miR-34a mimics for 48 hr before
immunoblot. b-Actin is a loading control. (D) miR-34a represses the 39UTR of CCND3, MCM2, MCM5, PLK1 and SMAD4, but not MCM4 and MYT1. HeLa
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growth factor signaling is so central to cell survival and
proliferation, the permanent loss of miR-34a expression likely
led to myriad compensatory changes. This seeming paradox
supports the conclusions of our study – namely that a single
miRNA may exert its biological effect by regulating expression of
hundreds of genes. The capacity of miR-34a to potentially regulate
so many genes that affect growth factor signaling may enable it to
exert an effect in diverse contexts.
The numbers of genes that are actually regulated by miR-34a in
any setting will likely depend on how strongly miR-34a is
expressed. In our pull-down, we greatly over-expressed miR-34a.
However, the level of over-expression throughout this study was
not greater than endogenous miR-34a expression in some
physiological settings, i.e. in K562 cells stimulated with phorbol
ester where miR-34a increases 1000-fold [9]. There may be a
target gene hierarchy – some genes regulated by low levels of miR-
34a, others regulated only by high levels.
The dense network of cell signaling genes captured in the pull-
downs suggests that an important function of miR-34a is to
regulate the proliferative and activation responses to extracellular
growth factors. Despite its function in regulating growth factor
signaling and cell proliferation, we did not find a significant
variation in miR-34a expression after serum starvation or when
cells were synchronized in different phases of the cell cycle (data
not shown). In this study we experimentally verified as direct miR-
34a targets 5 growth factor signaling genes (ARAF, AXL, MEK1,
MET and PIK3R2). miR-34a was previously shown to inhibit the
G1/S transition [3,8]. Here we identified 7 novel cell cycle-
regulating direct targets that included genes also required for DNA
replication and mitosis. The ultimate anti-proliferative effect of
miR-34a integrates both direct consequences of suppressing
expression of genes required for progression through the G1/S
transition and at other steps of the cell cycle as well as indirect anti-
proliferative effects from repressing the growth factor signaling
pathways that activate cell cycle progression. Consistent with our
genome-wide target gene analysis, miR-34a expression resets the
basal state of ERK and AKT phosphorylation in several cell lines,
rendering cells less responsive to growth factor signaling (Figure 5).
This was shown both by miR-34a overexpression as well as by
genetic deletion. miR-34a may reduce cellular sensitivity to growth
factor signaling by suppressing many genes in multiple signal
transduction pathways. miR-34a candidate targets include genes
that are universally involved in transmitting growth factor
activation signals as well as some that participate in specific
pathways. The particular signaling genes that are suppressed in a
given cell line will likely vary from cell to cell, depending on the
growth factors to which the cell responds. These types of
differences likely contribute to the incomplete overlap between
the enriched pathways captured in the two hematopoietic and
colon cancer cell lines examined here.
Materials and Methods
Cell lines
HCT116, K562, A549 and HeLa cells were from ATCC. miR-
34a
+/+ and miR-34a
2/2 MEFs were generated from E14.5
littermate embryos. A full description of the mice will be published
elsewhere. MEFs were transformed by infecting the cells with
retroviruses encoding H-RAS-V12 and E1A and by selection with
puromycin (1 mg/ml) and hygromycin (50 mg/ml). The plasmids
for expression of H-RAS-V12 (plasmid 9051) and E1A (plasmid
18748) were obtained from Addgene. The VSV-G pseudotyped
viruses were produced in 293T cells using the standard protocol.
MEFs, HCT116, A549 and HeLa cells were grown in DMEM
with 10% fetal bovine serum and supplemented with penicillin,
streptomycin, HEPES, L-glutamine and b-mercaptoethanol,
K562 cells were grown in RPMI containing 10% fetal bovine
serum and the same supplements.
Transfection of miRNA mimics and plasmid DNA
For most experiments, 2610
6 HCT116 or K562 cells were
transfected with 200 pmol hsa-miR-34a or cel-miR-67 miRNA
mimics (Dharmacon), using Amaxa nucleofection according to the
manufacturer’s protocol. Biotin was attached to the 39-end of the
active strand. HeLa and A549 cells were transfected with
Lipofectamine 2000 and miRNA mimics at a final concentration
of 50 nM (Invitrogen). To study the association of Bi-miRNAs
with HA-Ago1 or HA-Ago2, pIRESNeo (Clontech) or pIRESNeo-
HA-Ago1 or pIRESNeo-HA-Ago2 (Addgene) plasmids were co-
transfected in six-well plates (2 mg/well, 1610
6 cells/well) with
200 pmol Bi-miR-34a or Bi-cel-miR-67 using Amaxa as per the
manufacturer’s instructions.
RNA isolation and quantitative RT–PCR
Total RNA was isolated using Trizol reagent (Invitrogen), treated
with DNase I (Ambion) and reverse transcribed using random
hexamers and superscript III reverse transcriptase (Invitrogen).
qRT-PCR was performed in triplicate samples using SYBR Green
FastMix (Quanta) on a BioRad CFX96. mRNA levels were
normalized to housekeeping genes GAPDH, UBC or SDHA. miRNA
was quantified in triplicate using the TaqMan MicroRNA Assay
(Applied Biosystems) as per the manufacturer’s instructions and
normalized to U6. Primer sequences are listed in Table S3.
Immunoblot
Whole cell lysates from transfected K562 or HCT116 cells were
prepared using RIPA buffer. Proteins were analyzed by SDS-
PAGE, transferred to nitrocellulose membranes and probed with
the following antibodies: AXL [4566], ARAF [4432], MEK1
[9124], CDK4 [2906], MCM2 [3619], PKMYT1 [4282], PLK1
[4513], SMAD4 [9515], FOXP1 [2005], RBBP4 [4633], AKT
[9272], pAKT ser-473 [4051], ERK [4370], pERK [9107] from
Cell Signaling; MET [sc-161], MCM5 [sc-165995], E2F1 [sc-
251], E2F3 [sc-879], CHEK1 [sc-8408] from Santa Cruz;
ACSM3 [SAB1400253], MAD2L2 [SAB1400387], AGBL5
[AV53752], CCNG2 [AV03032], PSMD5 [WH0005711M1]
from Sigma; MCM4 [06-1296] from Millipore; and PI3KR
[610045], BD Biosciences. Western Blots were quantified by
densitometry.
Biotin pull-down
HCT116 or K562 cells (1610
6) were transfected in triplicate
with Bi-miR-34a or Bi-cel-miR-67 (Dharmacon) as described
cells were cotransfected for 48 hr with CTL miRNA or miR-34a mimics and psiCHECK-2 empty vector (V) or psiCHECK-2 containing the 39UTR of each
gene in the Renilla luciferase 39UTR. The positive control reporter contained a perfectly complementary sequence to miR-34a (AS-34a). Relative
luciferase activity in miR-34a-transfected cells is normalized to CTL miRNA-transfected cells. (E) Dual luciferase reporter plasmids bearing wild-type
(WT) MREs from CCND3, MCM2, MCM5 and SMAD4 are significantly repressed by co-transfection with miR-34a in HeLa cells. Mutation of the seed
region of each MRE (MT) rescues reporter expression. MRE sequences are provided in Figure S5. *, p,0.05, #,p ,0.01, **, p,0.005, ##,p ,0.001.
doi:10.1371/journal.pgen.1002363.g007
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later, the cells from 3 wells were pelleted at 5006g. After washing
twice with PBS, cell pellets were resuspended in 0.7 ml lysis
buffer (20 mM Tris (pH 7.5), 100 mM KCl, 5 mM MgCl2,0 . 3 %
NP-40, 50 U of RNase OUT (Invitrogen), complete mini-
protease inhibitor cocktail (Roche Applied Science)), and
incubated on ice for 5 min. The cytoplasmic lysate was isolated
by centrifugation at 10,0006g for 10 min. Streptavidin-coated
magnetic beads (Invitrogen) were blocked for 2 hr at 4uC in lysis
buffer containing 1 mg/ml yeast tRNA and 1 mg/ml BSA
(Ambion) and washed twice with 1 ml lysis buffer. Cytoplasmic
lysate was added to the beads and incubated for 4 h at 4uCb e f o r e
the beads were washed five times with 1 ml lysis buffer. RNA
bound to the beads (pull-down RNA) or from 10% of the extract
(input RNA), was isolated using Trizol LS reagent (Invitrogen).
The level of mRNA in the Bi-miR-34a or Bi-cel-miR-67 control
pull-down was quantified by qRT-PCR or mRNA microarray.
For qRT-PCR, mRNA levels were normalized to a housekeeping
gene (GAPDH, SDHA or UBC). The enrichment ratio of the
control-normalized pull-down RNA to the control-normalized
input levels was then calculated.
Microarray analysis
Total RNA (independently in two experiments) was amplified,
labeled and hybridized to Affymetrix U133 plus 2.0 mRNA
microarrays. The quality of the RNA was assessed before
performing the microarray and the quality of the microarray data
was assessed using affyPLM and Affy software. The replicate data
sets for the 4 sets of samples (pull-down and input for miR-34a and
cel-miR-67) were compared using an unsupervised hierarchical
clustering algorithm, which verified the similarity of the duplicates.
The microarray data were normalized using RMA [7] to reduce
interarray variation. The enrichment ratio {Bi-miR-34a PD/Bi-
cel-miR-67 PD}/{Bi-miR-34a input/Bi-cel-miR-67 input} was
calculated for each probe. For genes represented by multiple
probes, the mean ratio for all the probes was calculated. Genes for
which none of the probe hybridization signals exceeded the
background were considered not expressed and were disregarded
in the analysis. For informatic analysis of the PD data, genes whose
enrichment ratio were $1 SD above background based on a log-
normal distribution were considered ‘‘hits’’.
Gene down-regulation after miR-34a over-expression
HCT116 or K562 cells were transfected in independent
duplicate experiments as above with unbiotinylated miR-34a or
cel-miR-67 (Dharmacon) and total RNA was harvested 24 hr later
and analyzed as above by gene expression microarrays. After
normalization, fold changes for each probe were calculated as the
ratio of input RNA from miR-34a-transfected cells to the ratio of
input RNA from cel-miR-67-transfected cells. Genes were
considered down-regulated if the ratio decreased by at least
20%, which corresponded to ,1 SD. To test the expression levels
of putative target sets, each gene list was plotted in a cumulative
distribution function (CDF) plot, and the Kolmogorov-Smirnov
[KS] test was used for statistical comparisons between gene sets.
Analysis of miR-34a target genes by target prediction
algorithms
To determine whether a gene was also a predicted target of
miR-34a, the presence of miR-34a binding sites was analyzed
using TargetScan 4.2 (http://www.targetscan.org/) [39,54,55] or
PITA (http://132.77.150.113/pubs/mir07/mir07_prediction.
html) [50].
Hexamer analysis
The mature hsa-miR-34a sequence was obtained from miRBase
(http://mirbase.org/). All RefSeq human mRNA sequences were
downloaded from NCBI in July 2009 (http://ftp.ncbi.nih.gov/).
mRNAs were indexed by Entrez Gene ID; in cases where multiple
sequences matched a gene ID, the sequence with the longest
39UTR was selected. For each test gene list and miR-34a
hexamer, the miR-34a hexamer frequency (hexamer matches
per kb of sequence) was calculated. The frequency of hexamer
matches for all genes on the microarray (the background set) was
also determined. Gene IDs with no corresponding sequence in the
database were excluded from analysis. Monte Carlo simulations of
equally sized random gene sets (without replacement) were used to
generate an empirical 2-tailed p-value for each gene set/hexamer
combination. When p,1E-4, the p-value was calculated from
curve fitting relative to the random background distribution.
Pathway enrichment analysis and network visualization
For each of the lists of down-regulated and pull-down-enriched
genes, the p-value of over-representation in a suite of canonical
pathways (KEGG [56] and Wikipathways [57]) was determined
using the hypergeometric distribution. A visualization of the
relationship between the enriched pathways (p,0.001) based on
the number of overlapping genes was rendered using Cytoscape
[58]. The network of gene-gene interactions underlying these
relationships was constructed based on interactions supplied by
MetaCore (GeneGo Inc). Physical, predicted and genetic interac-
tions were used to connect the down-regulated and pull-down
enriched genes within the significant signaling, cell cycle or DNA
repair pathways. Signaling pathway genes with no connection to
any other node were removed and the network was arranged
according to predicted sub-cellular localization.
Luciferase assay
HeLa cells were cotransfected in 24 well plates using
Lipofectamine 2000 (Invitrogen) with 50 nM miR-34a mimic or
control miRNA mimic and 50 ng of psiCHECK2 (Promega)
vector containing the MRE or 39UTR of indicated genes cloned
into the multiple cloning site of Renilla luciferase. After 48 hr of
transfection (unless otherwise indicated) luciferase activities were
measured using the Dual Luciferase Assay System (Promega) and
Top count NXT microplate reader (Perkin Elmer) per manufac-
turer’s instructions. All experiments were performed at least in
triplicate. Results were normalized to those obtained in cells
transfected with an empty vector. For some experiments, a
perfectly complementary antisense sequence to the active strand of
miR-34a was inserted into the multiple cloning site for use as a
positive control. Data were normalized to Firefly luciferase and
results from 3 independent experiments were compared. Sequence
of primers used for cloning 39UTRs for miR-34a target genes are
listed in Table S4. MREs sequences were cloned into psiCHECK-
2 by annealing complementary oligomers matching each MRE
sequence (Figures S4, S5) with overhanging ends complementary
to the XhoI and NotI sites of psiCHECK-2.
Cell growth experiments
HCT116, HeLa and A549 cells were transfected as described
above. One day after transfection, cells were placed in serum-free
medium or medium containing 10% fetal calf serum. 48 hours
after the medium was changed, total cell numbers were counted.
MEFs were plated at a density of 2.5610
5 or 5610
5 cells per well
of a 6-well plate. The medium was changed to vary serum
concentration 24 hr after plating. The MEFs were harvested 24 hr
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PBS+0.4% BSA with annexinV-APC (Invitrogen) at a 1:30
dilution, then washed once and stained with propidium iodide
(4 mg/ml) (Sigma-Aldrich).
Supporting Information
Figure S1 (A) HCT116 cells were transfected with Bi-miR-34a
or Bi-cel-miR-67 (CTL) and after 24 hr, abundance of known
miR-34a target mRNAs (CDK4, CDK6 and MYB) was measured by
qRT-PCR analysis of pull-down RNA. CDK4, CDK6 and MYB
and not UBC (a housekeeping mRNA) were significantly enriched
in the Bi-miR-34a pull-downs (white) and not the control pull-
down (black). (B) K562 cells were transfected with Bi-miR-34a
(white) or Bi-CTL (black), and RNA isolated from the streptavidin
pull-down was analyzed by qRT-PCR for miR-34a and miR-24 (a
control miRNA) after normalization to U6. miR-34a was ,50-fold
higher in miR-34a pull-down as compared to control pull-down.
miR-24 was not enriched and its levels were similar in each pull-
down. (C) Addition of Bi-miR-34a (white) or Bi-CTL (black) to
cytoplasmic extracts prepared from untransfected K562 cells does
not enrich for known miR-34a target mRNAs, suggesting that the
specific association of these mRNAs with Bi-miR-34a occurs in
live cells and not post-lysis. Data in (B) are from 3 independent
experiments and in (A) and (C) are from duplicate experiments.
(TIF)
Figure S2 Sequence characteristics of Bi-miR-34a pull-down
targets. (A) Enrichment of hexamers matching each position of the
mature miR-34a sequence in the HCT116 and K562 pull-down
(red), down-regulated genes (blue), and genes down-regulated by
miR-34a and pulled-down (yellow). Genes both enriched by Bi-
miR-34a pull-down and down-regulated by miR-34a are the most
enriched for miR-34a seed matches (B) Hexamer enrichment
analysis for genes enriched in both HCT116 and K562 Bi-miR-
34a pull-downs. Bi-miR-34a pull-down enriched for sequences
matching two miRNA regions: the seed (positions 1–8) and a
possible 39 compensatory region (positions 13–19). Bi-miR-34a
pull-down mRNAs are also enriched for CDS and 59UTR
matches to these sequences (*p#0.0001).
(TIF)
Figure S3 Pathway networks representing the significant
canonical pathways enriched for TargetScan conserved (A) and
TargetScan non-conserved (B) target predictions.
(TIF)
Figure S4 miR-34a regulation of growth factor signaling. (A)
Western blots of A549 cells transfected with miR-34a or CTL
mimics. No reproducible change in pERK or pAKT was observed
in these cells. (B) A549 cells were transfected with miR-34a or cel-
miR-67 (CTL) mimics, and placed in normal growth medium with
10% serum (+) or growth medium lacking serum (2). Cells
transfected with miR-34a did not proliferate in response to serum.
Candidate miR-34a microRNA recognition elements (MRE) in
the 39UTR of AXL, ARAF, MEK1, MET and PIK3R2 mRNAs
predicted by PITA (see Materials and Methods). Numbers in
parenthesis represent the location of the MRE in the 39UTR.
Wild-type MREs in (C) were repressed by miR-34a (see Figure 5F)
whereas MREs that were not responsive to miR-34a are shown in
(D). Point mutations that disrupt the base-pairing with miR-34a
are shown in red in the mutant MREs.
(TIF)
Figure S5 Candidate miR-34a microRNA recognition elements
(MRE) in the 39UTR of CCND3, MCM2, MCM5, PLK1 and
SMAD4 mRNAs predicted by PITA or TargetScan (see Materials
and Methods). Numbers in parenthesis represent the location of
the MRE in the 39UTR (PLK1 MRE2 spans the stop codon of
PLK1). Wild-type MREs in (A) were repressed by miR-34a (see
Figure 6E), whereas MREs that were not responsive to miR-34a
are shown in (B). Point mutations that disrupt the base-pairing
with miR-34a are shown in red in the mutant MREs.
(TIF)
Table S1 Genes enriched in Bi-miR-34a pull-downs or down-
regulated by miR-34a over-expression in HCT116 and K562 cells.
(XLS)
Table S2 Experimental validation of miR-34a target genes.
(XLS)
Table S3 Sequence of primers used for qRT-PCR.
(XLS)
Table S4 Sequence of primers used for cloning 39UTR of miR-
34a target genes.
(XLS)
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